Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products

By Rajashekhar C
November 18, 2024

Let's Build a Healthier
& Safer World, Together

Connect with ClinChoice to discover how we can support the
development and commercialization of your drug or device.

Get In Touch